A study of SGT-001 for the treatment Duchenne muscular dystrophy (DMD).

Trial Profile

A study of SGT-001 for the treatment Duchenne muscular dystrophy (DMD).

Planning
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs SGT 001 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Mar 2017 According to a Solid Biosciences media release, the company anticipates to initiate this study in the second half of 2017.
    • 10 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top